Kephera Diagnostics unveils the first commercial testing panel for liver fluke infection
Kephera Diagnostics has introduced the first commercial liver fluke testing panel in the U.S., covering three species and utilizing ELISA technology to detect current and past infections, filling a critical diagnostic gap.
Kephera Diagnostics has announced the first commercial testing panel for liver fluke infection, offered through its CLIA laboratory. The panel includes tests for three liver fluke species, Clonorchis sinensis (Chinese liver fluke), Opisthorchis viverrini (Southeast Asian liver fluke) and Fasciola hepatica (Common liver fluke). Kephera had previously received $2.3 million in funding under SBIR contracts from the National Institutes of Health to support the development of these tests.
Kephera’s liver fluke panel detects antibodies to specific parasite biomarkers using an ELISA format. No tests for Clonorchis or Opisthorchis liver fluke infection are currently available from the CDC or other laboratories in the United States. As a serological test, the panel can detect evidence of both current and past infections. Further information and instructions for submitting samples for testing can be found on Kephera’s website, https://kephera.com.
